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Abstract
Background: The objectives of this study are to determine the incidence and sur-
vival rate of patients with head and neck squamous cell carcinoma (HNSCC) with
multiple primary tumors (MPT) in the HN-region, lung, or esophagus.
Methods: Patient and tumor specific data of 1372 patients with HNSCC were col-
lected from both the national cancer registry and patient records to ensure high-
quality double-checked data.
Results: The total incidence of MPTs in the HN-region, lung, and esophagus in
patients with HNSCC was 11% (149/1372). Patients with lung MPTs and esopha-
geal MPTs had a significant worse 5-year survival than patients with HN-MPTs
(29%, 14%, and 67%, respectively, P < 0.001). The 5-year survival rate for syn-
chronous HN MPTs was only 25%, whereas it was surprisingly high for patients
with metachronous HN MPT (85%, P < 0.001).
Conclusions: One of 10 patients with HNSCC develop MPTs in the HN-region,
lung, or esophagus. The 5-year survival of patients with metachronous HN MPTs
was surprisingly favorable.
KEYWORDS
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1 | INTRODUCTION
Head and neck cancer (lip, oral cavity, nasopharynx, oro-
pharynx, hypopharynx, and larynx) has an increasing inci-
dence with 686 000 new cases and 404 000 associated
mortalities worldwide in 2012.1 The majority of head and
neck tumors are squamous cell carcinoma (HNSCC).2 Due
to advances in surgical and radiotherapy and chemotherapy
techniques, the 5-year survival of patients with HNSCC has
improved from 55% in 1992-1996 to 66% in 2002-2006.3
This relatively low survival rate could be explained by high
tumor stages at diagnosis, patient delay before diagnosis,
and a high incidence of tumor recurrence.4–7 Another impor-
tant factor affecting survival might be the development of
multiple primary tumors (MPTs) in the head and neck region
(HN-region) but also in associated organs such as the lung
and esophagus.5,8
MPTs are squamous cell tumors, which develop at or after
diagnosis of the index tumor.9,10 Patients with second (SPT),
third, fourth, or even more primary tumors are defined as
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patients with MPTs. MPTs are not the same as a residual/recur-
rent tumors, which occur at the same site as the index tumor.
For patients with an index HNSCC, MPTs most frequently
occur in the HN-region, lung, or esophagus.5,11
The concept that explains the occurrence of MPTs is
field cancerization (FC). FC implies that tumors do not arise
as an isolated tumor but occur in a field of pre-neoplastic
squamous cells that have an anaplastic tendency. This ten-
dency gives rise to a multifocal development of tumors at
various rates within the field.12 For patients with HNSCC,
this FC is thought to extend as far as the lung and esopha-
gus.13 There are several theories that explain FC. The first is
the polyclonal theory, which states that multiple precursor
fields arise under the influence of carcinogenic agents.12 The
other theories are based on monoclonal concepts with a
spread of dysplastic cells, which give rise to new fields in
which MPTs may develop.14
The incidence of MPTs in patients with HNSCC is
reported to range from 9.4% to 14.4%.5 Most second primary
tumors (SPTs) occur in the HN-region (40%-59%), lung
(31%-37%), and esophagus (9%-44%).5 The overall survival
rate of patients who develop MPTs is lower than the survival
of patients with only a single primary tumor.6 A major
decrease of 5-year overall survival rates from 69% to 32%
has been reported for patients with metachronous MPTs
compared to patients without MPTs.15,16 It has even been
suggested that MPTs could have a worse effect on the sur-
vival of patients with HNSCC than residual/recurrent tumors
of the index tumor.5,17
In the literature, there is limited information available on
the incidence and impact of MPTs on the survival of patients
with HNSCC with a white ethnicity. Most studies on this
topic have been performed in Asia; therefore, the results
may not be generalizable for patients with HNSCC in West-
ern countries, because tumor incidences vary widely.18 Sub-
sequently, incidence and survival rates of patients with
MPTs could be underestimated or overestimated. Also,
cohorts that include a large number of patients are scarce.
The main objective of this study is to describe the inci-
dence of MPTs in a large Dutch cohort of patients with
HNSCC. The second objective is to analyze the effect of
MPTs on the survival rates of patients with HNSCC.
2 | PATIENTS AND METHODS
This article was written according to the STROBE guide-
lines for reporting observational studies.19 It was approved
by the Medical Ethics Committee of the Erasmus MC
(MEC-2016-751).
2.1 | Patients
Patients were selected from the Rotterdam Oncology Docu-
mentary (RONCDOC), which is a database that compromises
all patients with head and neck cancer treated at the Erasmus
MC Cancer Institute since 1995. We included all 1372 patients
who had been diagnosed with an HNSCC (lip, oral cavity,
nasopharynx, oropharynx, hypopharynx, larynx, and sinonasal
cavity) as index tumor between January 1, 2008 and December
31, 2011. The final date of follow-up was August 14, 2017.
No patients were excluded. Patients were divided into three
groups: patients who developed a second primary tumor in the
(a) HN-region, (b) lung, or (c) esophagus.
2.2 | Data collection
Patient, tumor, and therapy data were acquired from the
Netherlands Comprehensive Cancer Organization (a national
cancer registry in which all histologically proven cancers in
the Netherlands are registered—irrespective of the hospital
where the cancer is diagnosed) and merged with data from
the patient records of the Erasmus MC Cancer Institute. Sub-
sequently, the data were manually checked for each patient
using available data from the patient records. If there was
any doubt about the validity of the data collected, the
patient was discussed by the research staff until a consensus
was reached. A log was kept in which the inclusion of
patients was recorded. This leads to a high degree of classifi-
cation accuracy and low risk of selection bias. The following
data were collected: date of birth and death, last follow-up
date, comorbidity, prior malignancies, tobacco and alcohol
consumption, body mass index (BMI), clinical and histo-
pathologic TNM and tumor stage, type and intention of ther-
apy, and location and time to occurrence of MPTs.
Multiple primary tumors were defined according to the
Warren & Gates and Hong et al. criteria, which state that the
MPT (a) must be diagnosed as malignant on histologic
examination, (b) must be histologically distinct from the
index tumor and thus not a metastasis, (c) has to be at least
2 cm from the site of the index tumor or the tumor has to
occur > 3 years after the diagnoses of the index tumor.9,10
Patients with second, third, fourth, or even more primary
tumors (> 1 primary tumor) were identified as patients with
MPTs. An SPT is thus a first MPT. An MPT was defined as
synchronous if the tumor developed < 6 months after the
diagnosis of the index tumor and as metachronous if it
developed after ≥ 6 months.
A distinct differentiation should be made between MPTs
and residual/recurrent tumors, which occur at the same site
and share the same histopathology as the index tumor.
Residual tumors develop < 6 months after the index tumor
and recurrent tumors ≥ 6 months, but < 3 years. A tumor
developed at the same site as and ≥ 3 years after the index
tumor was considered to be an MPT.
Comorbidities were scored with the Adult Comorbidity
Evaluation-27.20 The intention of therapy was scored as
curative or palliative based on the Dutch guidelines for the
treatment of HNSCC, lung carcinoma, and esophagus carci-
noma.21 Height and weight were used to calculate the BMI.
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Patients were categorized as underweight (BMI < 18.5),
normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9),
and obese (BMI ≥ 30). Tobacco and alcohol use was regis-
tered as current-, previous- or non-smoker/drinker. For
tobacco use, the number of pack-years was registered and
for alcohol use the number of units per week was registered.
2.3 | Statistical analysis
If quantitative variables were normally distributed, the
results are expressed as mean values and SD; otherwise
median and interquartile range (IQR) are used. Categorical
data are reported as frequencies and percentages, and differ-
ences between groups were analyzed using the chi-squared
test. A Kaplan-Meier survival analysis was used for survival
analyses and the log-rank test to compare the survival distri-
butions of two groups of patients. The 5-year survival from
the date of diagnosis of the index tumor was analyzed and,
additionally, the 3-year survival rate from the date of diagno-
sis of the SPT was analyzed. The survival rate was analyzed
separately for patients with synchronous a metachronous
SPTs. A complete case analysis was used to handle missing
data. However, all data on the outcomes of interest (inci-
dence and survival) were complete. Statistical analysis was
performed using SPSS version 21.0 (IBM Corp., Armonk,
New York).
3 | RESULTS
3.1 | General patient and index tumor characteristics
A total of 149 patients with multiple primary tumors and
an HNSCC as index tumor were identified in our cohort.
Their baseline characteristics are shown in detail in
Table 1. The mean duration of follow-up was 51.9 months
(SD 27.9). One hundred eleven patients (74.5%) were men
and their mean age was 63.1 years (SD 8.8). The
majority of patients was a current smoker (114 [76.5%]).
This group had a median number of 42.0 pack-years (IQR
33.0-58.8). The majority of patients was also current alco-
hol abusers (114 [76.5%]), who had a median alcohol con-
sumption of 28 units per week (IQR 14-42). There were
110 patients (73.8%) with mild to severe comorbidity.
Table 2 provides a detailed overview of the characteris-
tics of the HNSCC index tumor. Most tumors were in the
oral cavity (46 [30.9%]), followed by the oropharynx
(40 [26.8%]) and the supraglottic region (28 [18.8%]. The
tumor stage ranged from 0 (carcinoma in situ) to
IV. Radiotherapy was the most frequently used therapy
(52 patients [34.9%]), whereas 36 patients (24.2%) received
TABLE 1 Patient characteristics
Number of patients 149
Follow-up, mean (SD), mo 51.9 (27.9)
Male sex, n (%) 111 (74.5)
Age, mean (SD), y 63.1 (8.8)
Smoking status, n (%)/median PY (IQR)
Current smoker 114 (76.5)/42 (33-59)
Previous smoker 27 (18.1)/40 (25-50)
Nonsmoker 7 (4.7)/0 (0–0)
Missing 1 (0.7)
Alcohol consumption, n (%)/median UPW (IQR)
Current drinker 114 (76.5)/28 (14–42)
Previous drinker 22 (14.8)/28 (14–42)
Nondrinker 12 (8.0)/0 (0–0)
Missing 1 (0.7)
Comorbiditya, n (%)
None 39 (26.2)
Mild 57 (38.2)
Moderate 31 (20.8)
Severe 22 (14.8)
Body mass index, n (%)
Underweight (< 18.5) 10 (6.7)
Normal weight (18.5–24.9) 78 (52.3)
Overweight (25.0-29.9) 47 (31.5)
Obese (≥ 30) 9 (6.2)
Missing 5 (3.3)
Abbreviations: PY, pack-years; UPW, units per week.
a Comorbidity measured by Adult Comorbidity Evaluation 27.
TABLE 2 Characteristics of index tumor (n = 149)
Characteristics n (%)
Tumor location
Lip 2 (1.3)
Oral cavity 46 (30.9)
Oropharynx 40 (26.8)
Hypopharynx 11 (7.4)
Supraglottic 28 (18.8)
Glottis 18 (12.1)
Sinonasal cavity 4 (2.7)
Tumor stage
0 (CIS) 6 (4.0)
I 39 (26.2)
II 34 (22.8)
III 26 (17.4)
IV 43 (28.9)
Missing 1 (0.7)
Therapy
Surgery 36 (24.1)
Radiotherapy 52 (34.9)
Chemotherapy 0 (0.0)
Surgery + RT 32 (21.5)
RT + CT 20 (13.4)
Surgery + RT + CT 5 (3.4)
No therapy 4 (2.7)
Intention of the therapy
Curative therapy 141 (94.6)
Palliative therapy 8 (5.4)
Residual tumors 0 (0.0)
Recurrent tumors 12 (8.1)
Abbreviations: CIS, carcinoma in situ; CT, chemotherapy; RT, radiotherapy.
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surgery. Thirty-two patients (21.5%) received surgery with
adjuvant radiotherapy. Twenty patients (13.4%) received a
combination of radiotherapy and chemotherapy. Recur-
rences of the index tumor occurred in 12 (8.1%) of the
149 cases. No residual tumors were detected.
3.2 | MPT incidence and time to occurrence
Figure 1 presents the distribution of the MPT development
during follow-up. A total of 1372 patients with an HNSCC
index tumor were diagnosed at the Erasmus MC Cancer
Institute between 2008 and 2011. The total incidence of
MPTs in patients with HNSCC was 10.9% (n = 149). The
SPT of these patients was located in the HN-region in 5.5%
of the cases (n = 75), in the lung in 4.9% of the cases
(n = 63), and in the esophagus in 0.8% (n = 11). Of these
patients with an SPT, 19.5% (29/147) also developed a third
primary tumor (TPT). Seven patients with TPTs (24.1%)
even developed more than three primary tumors.
The median time to occurrence of all SPTs was
22.9 months (IQR 2.1-47.4). The head and neck-SPTs (HN-
SPTs) were synchronous in 23 cases (30.7%), with a median
time to occurrence of 0.1 months (0.0-0.9). Fifty-two HN-
SPT cases (69.3%) were metachronous, with a median time
to occurrence of 41.7 months (IQR 19.0-58.0). The index
tumors of patients with metachronous HN-SPTs were more
often advanced (stage III and IV) than synchronous
HN-SPTs (56.5% vs 26.9%). The SPTs in the lung were syn-
chronous in 18 cases (28.6%) and had a median time to
occurrence of 1.8 months (IQR 1.0-2.7). Forty-five lung-
SPTs (71.4%) occurred metachronously and had a median
time to occurrence of 37.1 months (IQR 22.7-55.0). Almost
a quarter (n = 3) of the SPTs in the esophagus developed
synchronously and the other 72.7% (n = 8) metachronously.
The median time to occurrence from the index tumor to the
TPT was 34.5 months (IQR 11.2-60.0).
3.3 | Survival analysis
The survival of all 149 patients with MPTs was analyzed.
Their overall 5-year survival, measured from the occurrence
of the index tumor, was 46.8%. The 5-year survival of
patients who developed an HN-SPT (67.3%) was better than
patients who had a lung-SPT (28.6%, P < 0.001) or an
esophageal-SPT (13.6%, P < 0.001) (Figure 2).
Figure 3A shows that patients with synchronous HN-
SPTs had a worse 5-year survival rate (24.5%) than patients
with metachronous HN-SPTs (84.6%, P < 0.001). The
5-year survival of patients with a synchronous SPT in the
lung (16.7%) was also worse than those with metachronous
lung-SPTs (33.3%, P = 0.003). Patients with metachronous
lung-SPTs had a lower 5-year survival rate than patients
with metachronous HN-SPTs (P < 0.01). On the other hand,
the survival of patients with a synchronous SPT in the lung
and HN-region was not significantly different (P = 0.19).
The median survival of patients with synchronous HN-
SPTs was 3.2 years (IQR 1.1-4.4), whereas it was 6.1 years
(IQR 4.8-7.5) for metachronous cases. The median survival
of patients with synchronous lung-SPTs was 1.6 years (IQR
0.7-3.5) and 4.0 years (IQR 2.7-5.9) for patients with meta-
chronous lung-SPTs. Due to the limited number of patients
with an esophageal-SPT, we were not able to analyze differ-
ences between metachronous and synchronous SPTs in this
group.
Figure 3B shows the 3-year survival rate, measured from
the moment the SPT was diagnosed. This was the same for
patients with a synchronous (59.8%) and metachronous
HN-SPT (62.8%). A difference was seen in the group of
FIGURE 1 Flowchart presents the distribution of the multiple primary tumor development in patients with head and neck cancer. HN, head and neck; MPT,
multiple primary tumor; SPT, second primary tumor; TPT, third primary tumor
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patients with lung-SPT. Patients with metachronous lung-
SPTs had a worse 3-year survival rate (9.9%) than patients
with synchronous lung-SPTs (33.3%, P = 0.048). Metachro-
nous lung-SPTs were more often diagnosed in a high stage
(stage III and IV) of development (34 [75.6%]) than syn-
chronous lung-SPTs (9 [50.0%], P = 0.049) and also more
often than metachronous HN-SPTs (21 [40.4%], P < 0.001).
4 | DISCUSSION
This study showed that 1 of 10 patients with HNSCC
develop at least one multiple primary tumor (MPT) in the
HN-region, lung, or esophagus. We acquired our results by
using high-quality, double-checked data obtained from the
national cancer registry and the patients records. Surpris-
ingly, MPTs develop as frequently in lung (4.9%) as in the
HN-region (5.3%). The 5-year survival rate of all patients
was 47%. This is lower than the 66% stated in the litera-
ture.3,22 Patients with MPTs that were synchronous or in the
lung or esophagus had the worst survival. On the other hand,
patients with metachronous HN-SPTs had a surprisingly
high 5-year survival rate of 85%.
We showed that the 5-year survival rate of patients with
HNSCC with a synchronous HN-SPT was significantly
worse than patients with a metachronous HN-SPT. This
finding is similar to the results of two previous studies.23,24
This could be explained by the higher percentage of high-
stage tumors (stage III and IV) in the synchronous HN-SPT
FIGURE 3 (A) The 5-year survival from the diagnosis of the head and neck index tumor for patients with synchronous and metachronous second primary
tumors in the head and neck region and the lung. (B) The 3-year survival from the diagnosis of the second primary tumor for the same patients. Numbers at
the bottom of the figure represent patients at risk. * P < 0.001 compared to meta HN, † P < 0.001 compared to meta HN, ‡ p = 0.048 compared to syn lung.
P-values calculated with log-rank test. HN, head and neck; meta, metachronous; Syn, synchronous [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 The 5-year survival from the diagnosis of the HN index tumor
for patients with second primary tumors in the HN-region, the lung, and the
esophagus. Numbers at the bottom of the figure represent patients at risk.
*P < 0.001 compared to HN; † P < 0.001 compared to HN. P-values
calculated with log-rank test. HN, head and neck [Color figure can be
viewed at wileyonlinelibrary.com]
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group (56%) compared to the metachronous HN-SPT group
(40%). However, this difference was not significantly differ-
ent, P = 0.2. Another explanation is that the development of
a synchronous MPT in the HN-region limits the treatment
options of the index tumor. Panosetti et al. showed that treat-
ment protocols of the index tumor need to be adjusted when
a synchronous SPT is diagnosed.23 The treatment strategy
had to be adjusted in 50% of patients with HNSCC with a
synchronous HN-SPT. Subsequently, this adjustment caused
a decline in the 5-year survival rate from 18% to 8%.
The location of the SPT was also of significant influence
on the survival. Although the incidence of SPTs in the HN-
region and lung were almost the same in the present study,
the 5-year survival of patients who developed an SPT in the
lung (29%) was significantly worse than that of the patients
with HN-SPTs (67%). The survival rate of patients with
esophageal-SPTs was even lower (14%). These findings are
in line with the results of other studies.15,25
Interestingly, the 3-year survival rate, measured from the
occurrence of the SPT, was the same for patients with syn-
chronous and metachronous HN-SPTs (61% vs 63%). On the
other hand, it was significantly lower for patients with lung-
SPTs: 33% for synchronous and 10% for metachronous
MPTs. The difference between the 5-year survival (from the
index tumor) and 3-year survival (from the SPT) of meta-
chronous SPTs could be explained by the long median time
to occurrence. This indicates that synchronous and meta-
chronous SPTs have a similar mortality and that the time to
occurrence of an SPT is what dictates patient survival. The
first 6 months after the index tumor are important for the
prediction of survival of an individual patient. Patients who
developed an SPT within this period (synchronous) have a
significant worse 5-year survival rate, measured from the
index tumor, than patients who stayed free of an SPT for the
first 6 months (metachronous).
The majority of metachronous lung-SPTs were diag-
nosed in stage III or IV (76%). This could be an explanation
of the lower survival rate in this group compared to patients
with synchronous lung-SPTs or metachronous HN-SPTs.
Many patients with high-stage lung tumors are incurable,
and if treatment is available, it often induces severe comor-
bidity.26 To our knowledge, all current follow-up protocols
for patients with HNSCC lack an active screening for
MPTs in the lung, despite the evident negative effect of
lung-MPTs on patient survival and the similar incidence as
HN-MPTs. Screening for lung-MPTs could be considered
because of the low survival rate of affected patients and the
high percentage of high-stage lung-MPTs.24,27
Several studies also advocate the use of surveillance and
screening for esophageal-MPTs.28 A French multicentered
study investigated the use of endoscopy of the esophagus in
the work-up of patients with HNSCC to screen for MPTs.
They found an eight-times higher percentage of 6.8% esoph-
ageal carcinoma and high-grade dysplasia than the 0.8% in
our study.29 A study by De Vries et al. also showed high
percentages of esophageal-MPTs in a cohort of Dutch
patients with HNSCC.8 Several Asian studies have even
shown esophageal-MPT incidences of up to 41%.30–33
Therefore, we believe our incidence of esophageal-MPTs is
an underestimation of the actual incidence. This discrepancy
between the literature and our findings could indicate that
many esophageal-MPTs are never diagnosed, despite the fact
that diagnosis of early stage esophageal-MPTs could
improve the outcome of patients with HNSCC.34 It is even
suggested that early esophageal-MPT diagnosis and treat-
ment could give these patients a similar prognosis as patients
who did not developed an esophageal-MPT.35 These find-
ings suggest that endoscopic screening for esophageal-MPTs
in the workup of patients with HNSCC might cause a health
benefit.
We showed an increasing risk to develop an MPT in
patients who already have an MPT. The incidence increased
from 11% for an SPT in patients with an HSNCC index
tumor up to 24% for a fourth primary tumor in patients with
three primary tumors. These findings are in line with the
multifocal development of tumors within a precursor field,
stated by the FC theory.12 Other literature showed that a con-
tinuous exposure to carcinogenic agents like smoking and
alcohol and possibly radiotherapy treatment also increases
the risk to develop an MPT.36 The increasing incidence and
the FC theory combined give rise to the question whether
patients with MPT can be completely cured.
No residual tumors were detected in this cohort, and the
rate of recurrent tumors was 8.1%. This is relatively low,
compared to a recent review that reported local residual/
recurrence rates varying from 10% to 50%, depending on the
location and stage of the primary tumor.11 This could be
explained by the fact that all our patients have MPTs. Lester
et al. stated that 85% of all recurrences appear after
13-31 months.37 In comparison, the median time to occur-
rence of all SPTs in the present study was 23 months (IQR
2-47). This could mean that a selection of our patients might
have died as a consequence of an MPT before a recurrence
could have developed. It could also indicate that less recur-
rences were diagnosed because diagnostics and treatment
were focused on the MPT.
There are limitations to the present study that might have
had an influence on the results we obtained. One is the rela-
tively small number of patients with esophageal-MPTs. This
prevented us to perform a detailed survival analysis in this
group of patients. Another limitation is the absence of a con-
trol group of patients with HNSCC who did not develop an
MPT. Consequently, we had to compare the survival of our
patients with MPTs with previously reported data of patients
with HNSCC without MPTs. This also prohibited us to com-
pare the difference in effect on survival between MPTs and
residual/recurrent tumors and to identify risk factors and risk
profiles for the occurrence of MPTs. It could also be argued
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to exclude patients with tumors with a known low risk to
develop multiple primary tumors (HPV-negative oropharyn-
geal and sinonasal tumors). However, they were a minority
of our total study population. Another point of concern is the
fact that the distinction between a lung-MPT and a distant
lung metastasis is challenging—ideally, identification of
genetic relation between both tumors. In this study, loss-of-
heterozygosity analysis was performed in most cases of lung
cancer. However, some exceptions were made for patients
with (a) lung tumors that developed >5 years after the index
HNSCC tumor and (b) patients who were treated with a pal-
liative intent because of stage IV lung tumors. Despite these
limitations, our protocolled method of data collection and
large total cohort size made it possible to draw reliable con-
clusions from our results.
In conclusion, about 1 in 10 patients with HNSCC devel-
oped MPTs in the HN-region, lung, or esophagus. This
could be explained by the FC theory. MPTs had a negative
effect on the survival, which was most pronounced in
patients with MPTs which were synchronous or in the lung
or esophagus. Patients with metachronous MPT in the HN-
region had a surprisingly good 5-year survival rate. Screen-
ing and a better follow-up might be considered to increase
the overall survival of patients with HNSCC because of the
high incidence and the negative effect on survival. This spe-
cifically applies to MPTs that develop in the lung and esoph-
agus. Future goals of research are to compare patients with
HNSCC with and without MPTs and identify risk factors
and risk profiles for their development.
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